

Please cite the Published Version

Tinnion, Daniel ^(D), Dobson, Ben ^(D), Hilton, Nathan ^(D), McNaughton, Lars R ^(D) and Sparks, S Andy ^(D) (2024) The Magnitude of the Blood Acid-Base Response, but Not Time to Peak, Is Reliable Following the Ingestion of Acute, Individualized Sodium Citrate. International Journal of Sport Nutrition and Exercise Metabolism. pp. 1-9. ISSN 1526-484X

DOI: https://doi.org/10.1123/ijsnem.2024-0122

Publisher: Human Kinetics

Version: Accepted Version

Usage rights: (cc) BY

Downloaded from: https://e-space.mmu.ac.uk/637503/

Creative Commons: Attribution 4.0

Additional Information: This is an author accepted manuscript which first appeared in International Journal of Sport Nutrition and Exercise Metabolism, by Human Kinetics. This version is deposited with a Creative Commons Attribution 4.0 licence [https://creativecommons.org/licenses/by/4.0/], in accordance with Man Met's Research Publications Policy. The version of record can be found on the publisher's website: https://doi.org/10.1123/ijsnem.2024-0122.

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines) The magnitude of the blood acid-base response but not time to peak is reliable
 following the ingestion of acute individualized sodium citrate

3

4 Abstract

5 Enhanced buffering capacity following sodium citrate (SC) ingestion may be optimised when 6 subsequent exercise commences at individual time-to-peak (TTP) alkalosis (blood pH or 7 bicarbonate concentration ([HCO₃-]). While accounting for considerable inter-individual 8 variation in TTP (188-300 min), a reliable blood alkalotic response is required for practical 9 use. This study evaluated the reliability of blood pH, [HCO₃-] and [Na⁺] following acute SC 10 ingestion. Fourteen recreationally active males ingested 0.4 or 0.5 g kg⁻¹ body mass (BM) of 11 SC on two occasions each and 0.07 g kg⁻¹ BM of sodium chloride (CON), once. Blood pH and 12 $[HCO_3^-]$ were measured for 4 h post-ingestion. Blood pH and $[HCO_3^-]$ displayed good reliability following 0.5 g kg⁻¹ BM SC (r = 0.819, p = 0.002, sTE = 0.67 and r = 0.840, p < 0.001, sTE = 13 14 0.63, respectively). Following 0.4 g kg⁻¹ BM SC, blood [HCO₃-] retained good reliability (r =15 0.771, p = 0.006, sTE = 0.78), versus moderate for blood pH (r = 0.520, p = 0.099, sTE = 16 1.36). TTP pH was moderately reliable following 0.5 (r = 0.676, p = 0.026, sTE = 1.05) and 17 0.4 g kg⁻¹ BM SC (r = 0.679, p = 0.025, sTE = 0.91) versus poor for [HCO₃⁻] following 0.5 (r = 18 0.183, p = 0.361, sTE = 5.38) and 0.4 g kg⁻¹ BM SC (r = 0.290, p = 0.273, sTE = 2.50). While 19 the magnitude of (and displacement in) blood alkalosis, particularly [HCO₃] appears reliable 20 following potentially ergogenic doses of SC, strategies based on individual TTP cannot be 21 recommended.

22

23 Keywords

- 24 Acidity, buffering and individual response
- 25
- 26
- _
- 27
- 28

29

30

31

32 Introduction

33 Exercise bouts including high-intensity and endurance-intensive efforts (>6 s to ≥1 min) are 34 associated with high levels of glycolytic flux (van Loon et al., 2001; Romjin et al., 1993) and 35 reductions in muscle and blood pH and bicarbonate concentration ([HCO₃-]) (Fitts, 1994). 36 Peripheral fatigue may develop when any of the associated regulatory/support systems cannot 37 promote the necessary muscular contractile force and/or sustain the bioenergetics and 38 metabolic biproduct removal required to maintain exercise intensity (Keyser, 2010). For 39 example, greater hydrogen ion (H⁺) production versus removal, represents the limits of 40 endogenous HCO₃- buffering capacity. Buffering agents such as sodium citrate (SC) are 41 ingested to increase blood alkalosis (increasing both blood [HCO3-] and pH), with 42 simultaneous increases in blood electrolytes, particularly sodium (Na⁺). The resultant 43 alteration to the intracellular-extracellular pH gradient promotes upregulation of the lactate-H⁺ 44 co-transporter, supporting greater efflux of H⁺ from the muscle (Bishop et al., 2004). Current recommendations propose ingesting 0.4-0.5 gkg⁻¹ body mass (BM) SC to ensure sufficient 45 46 alkalosis to improve performance, while greater doses may promote additional gastrointestinal 47 symptoms (GIS) (Urwin et al., 2021b; Cerullo et al., 2020). Urwin et al. (2021b) found that SC 48 was most frequently associated with performance improvements when 0.5 g kg⁻¹ BM was 49 ingested, relative to < 0.5 or > 0.5 g kg⁻¹ BM. McNaughton et al. (1990) partly support this, 50 observing greater total work and peak power output during a 60 s cycle sprint post-ingestion 51 of 0.5 compared to 0.4, 0.3, 0.2 and 0.1 g kg⁻¹ BM SC and a placebo. In their review, Urwin et 52 al. (2021b) noted that no studies implementing > 0.5 $g kg^{-1}$ BM SC reported a performance 53 benefit versus placebo, irrespective of exercise duration/intensity. Cerullo et al. (2020) 54 recommend 0.4 g kg⁻¹ BM based on a lone study by Hausswirth et al. (1995) who linked 0.4 g kg⁻¹ BM SC with increased endurance time during prolonged isometric knee extension at 55 56 35% of the maximum voluntary contraction (MVC). Therefore, 0.4 g·kg⁻¹ BM SC potentially represents a minimum effective dose. Greater effects post-ingestion of extracellular buffers are purported when increases in blood [HCO₃⁻] are medium (4-6 mmol·L⁻¹) and large (> 6 mmol·L⁻¹) compared to small (\leq 4 mmol·L⁻¹) (de Oliveira et al., 2021). Accordingly, SC induces large increases in blood [HCO₃⁻] of up to 8.9 mmol·L⁻¹, although the time-to-peak (TTP) is subject to substantial inter-individual variability (Urwin et al., 2022; 2021a; 2019).

62

63 Post-ingestion of 0.5 g kg⁻¹ BM SC, individual TTP [HCO₃⁻] may range between 148-212 min 64 when administered aqueously (Urwin et al., 2016; 2019), compared to 188-300 (Urwin et al., 65 2022; 2021a; 2019) and \sim 145 (± 28) min (Peacock et al., 2021) when encapsulated in gelatine 66 and delayed-release forms, respectively. Given SC has typically been administered at 67 generalised timepoints pre-exercise (i.e., 60 or 90 min), replicating responses following SB 68 (de Salles Painelli & Junior, 2018), it is unlikely that research has appropriately timed exercise 69 with increases in blood [HCO₃⁻] at/around peak (Urwin et al., 2021b). Accordingly, an unclear 70 effect of SC (0.0% (±1.3%)) on performance remains (Carr, Hopkins & Gore, 2011).

71

72 Commencing exercise alongside individual TTP alkalosis (blood pH and/or [HCO₃-]) provides 73 a potential strategy to account for inter-individual variation post-ingestion of buffering agents, 74 with a growing body of research in SB (Lassen et al., 2021; Boegman et al., 2020; Gough et 75 al., 2017a; 2017b; Miller et al., 2016). Only Boegman et al. (2020) directly compared an 76 individualised (40-160 min pre-exercise) to a generalised approach (60 min pre-exercise). 77 They observed significantly improved 2000 m rowing time-trial performance for 18/23 world-78 class rowers (individualised = 367.0 ± 10.5 s vs. generalised = 369.0 ± 10.3 s). This followed 79 differences only small pre-exercise blood [HCO₃-] in 80 (individualised = + 6 mmol·L⁻¹ vs. generalised = + 5.5 mmol·L⁻¹) suggesting that a maximal 81 increase rather than 'meaningful' increase within proposed thresholds (i.e., 4-6 mmol L^{-1} +) 82 could provide added benefit, although other mechanisms/perspectives are plausible (Newbury 83 et al., 2021; de Oliveira et al., 2020).

84

For application of TTP, understanding the reliability of the blood alkalotic response ([HCO₃⁻] and pH) following acute SC is necessary. Many metabolic reactions either produce or consume acids and bases, with net endogenous acid production (NEAP) regulated primarily by diet. Given variations in NEAP may impact acid-base balance, the applicability of an individualised approach based on blood alkalosis is contingent on the reliability of these analytes day-to-day (Poupin et al., 2012; Remer, 2001).

91

92 Gough et al. (2017a) previously investigated the reliability of the blood alkalotic response post-93 ingestion of 0.2-0.3 g kg⁻¹ BM SB, provided aqueously. Data support the use of an 94 individualised strategy, with blood [HCO₃] and pH demonstrating good reliability for TTP and 95 absolute change. No such investigation has explored this following acute SC ingestion. 96 Moreover, building evidence now favours encapsulation over solution to mitigate GIS post-97 ingestion of extracellular buffers (Peacock et al., 2021; Urwin et al. 2021b; 2019). Therefore, 98 the aim of the current research was to evaluate the reliability of individual blood pH, HCO₃-99 and Na⁺ responses post-ingestion of 0.4 and 0.5 g kg⁻¹ BM of SC, provided in gelatine 100 capsules.

101

102 Method

103 **Participants**

104 Participants were invited based on their engagement in any sport/activity that may benefit from 105 an enhanced buffering capacity (Urwin et al. 2021b). Fourteen recreationally active males 106 (height 1.81 \pm 0.55 m, BM 81.4 \pm 8.9 kg, age 27 \pm 4 years, peak oxygen uptake [VO_{2peak}] 41.4 107 ± 13.0 ml·kg⁻¹·min⁻¹) volunteered for this double-blind, randomised crossover study. Ethical 108 approval was granted by institutional research ethics sub-committee (SPA-REC-2019-252R1). 109 Each participant provided written informed consent and completed health screening before 110 commencing data collection. Participants were also screened to confirm they had not ingested 111 intra- or extracellular buffering agents within the last six months and were not restricting Na⁺ 112 intake.

113

114 **Pre-experimental Procedures**

115 Participants reported to the laboratory on six separate occasions, 4 h postprandial and at the 116 same time of day (~09:00) to minimise circadian variability (Johnston, 2014). Participants were 117 asked to avoid alcohol and any strenuous/unaccustomed exercise for 24 h prior to each visit 118 (Lieber, 2000). Caffeine was also prohibited 12 h before each visit to limit disturbances to 119 metabolic regulation (Westerterp-Platenga et al., 2006) and mitigate additional GIS risk 120 (Boekama et al., 1999). Adherence to pre-experimental controls was confirmed verbally prior 121 to each trial. Visits were conducted at least 48 h apart to facilitate washout of residual SC 122 (Urwin et al., 2021a).

123

124 Determination of VO_{2peak}

125 Peak VO₂ was determined utilising a ramp test. This test began with 5-min unloaded pedalling 126 into a ramped increase of 0.5 Watts per second (W s⁻¹), equating to 30 W min⁻¹. A preferred 127 cadence between 70-90 rpm was selected pre-test, with participants asked to maintain this 128 cadence to within 10 rpm, until volitional exhaustion despite strong encouragement for 10 s. 129 Tests were performed on an electromagnetically braked cycle ergometer (Lode Excalibur, 130 Germany). Breath-by-breath gases were continuously analysed using a gas analyser (K5, 131 Cosmed, Italy) to measure oxygen uptake (VO₂), carbon dioxide production (CO₂) and the 132 respiratory exchange ratio (RER). The VO_{2peak} was determined by averaging VO₂ over the final 133 30 s of exercise.

134

135 **Supplementation Trials**

The five supplementation trials were randomised using a Latin square and involved one control trial requiring the ingestion of 0.07 g·kg⁻¹ BM of sodium chloride (CON), two trials requiring the ingestion of 0.4 g·kg⁻¹ BM (SC4a and SC4b) or 0.5 g·kg⁻¹ BM (SC5a and SC5b) SC. Both sodium chloride and SC (Pro Athlete Supplementation, Rhymney, UK) were administered in opaque (white), size '00' gelatine capsules (Bulk Powders[™], Colchester, UK), which were prepared by a laboratory technician not involved with the research. Capsules were consumed with 500 ml of room temperature (18°C) water within 15 minutes (Urwin et al., 2021a). To aid blinding, capsule number was matched to that provided in the 0.5 g·kg⁻¹ BM trials (55 \pm 6), using cornflour to fill the remaining capsules.

145 An initial arterialised fingertip capillary blood sample was obtained from participants whilst 146 seated and rested pre-ingestion. After capsules were ingested (<10 min), blood samples were 147 taken every 17 min for 4 h. A heated blanket (45°C) was used to warm the hand prior to each 148 sample to assist with blood sampling (Gough et al., 2017a). At each interval, a GIS 149 questionnaire was completed to assess the severity of a range of symptoms on a visual 150 analogue scale (VAS) where 0 = no symptom and 10 = most severe (Gough et al., 2024). 151 Participants were asked to remain seated with only toilet breaks allowed. No food was 152 consumed during testing, although water was consumed ad libitum in the first trial and 153 replicated thereafter. Blood samples were collected in 100 µl heparin-coated clinitubes 154 (Radiometer Medical Ltd, Denmark) and analysed for blood pH, HCO₃⁻ and Na⁺ using a blood 155 gas analyser (ABL800 BASIC, Radiometer Medical Ltd). This device has demonstrated low 156 bias in the measurement of pH, partial pressure of CO₂ (PCO₂) and Na⁺ (Radiometer Medical, 157 2015) and a correlation coefficient of r > 0.98 for both HCO₃⁻ and pH, against other blood gas 158 analysers (Stadlbauer et al., 2011).

159

160 Statistical Analysis

161 An a priori power calculation was completed using SPSS Sample Power 3 (IBM, Chicago, IL, 162 USA) based upon an expected population correlation of r = 0.80, suggesting that a minimum 163 of 11 participants were required to achieve 80% power (P < 0.05). An additional 3 participants 164 were recruited to account for any potential dropouts. Assessed variables were initially 165 analysed for normality (Shapiro-Wilks and Q-Q plots) and homogeneity of variance/sphericity 166 (Mauchly). Both one-way (treatment) and two-way (treatment/time) repeated measures 167 analysis of variance (ANOVA) were used to deduce differences in blood parameters with 168 Bonferroni pairwise comparisons. Where sphericity was violated, the Greenhouse Geiser 169 correction was applied. Effect sizes were calculated using generalised eta squared (η_G^2) , 170 where 0.099-0.0587, 0.0588-0.1378 and \geq 0.1379 represent small, medium and large effects, 171 respectively (Cohen, 1988). For nonparametric data, where the distribution of data was similar between groups, such as GI symptom scores, the median test was used with H scores, 172 173 degrees of freedom and significance reported. For GIS, total symptoms (sum of each 174 individual reported score) and TTP severity (first instance at which the largest individual score 175 occurred) were used to determine overall GIS responses. Statistical significance was set at p 176 <0.05. Heteroscedasticity was assessed using Bland-Altman plots. Test-retest reliability 177 between conditions was evaluated using intraclass correlation coefficients (ICCs), coefficient 178 of variation (CV) [(SD)/mean x 100] and standardised technical error (sTE) (Hopkins, 2000), 179 based on dose-response, determined using area under the curve (AUC) analyses. For ICCs, 180 r < 0.5 = poor, 0.5-0.75 = moderate, 0.75-0.9 = good and > 0.9 = excellent reliability (Koo and181 Li, 2016). Ranges for CV (%) are interpreted as >20% (very poor), >10% (poor), <10% 182 (acceptable), <5% (good) and >2% (excellent) (Stables et al., 2021). Interpretation of sTE 183 utilised a modified Cohen scale, describing < 0.2 as trivial, 0.2-0.6 as small, 0.6-1.2 as 184 moderate, 1.2-2.0 as large and > 2.0 as very large (Sparks et al., 2016). Where data was non-185 normally distributed, log transformation was performed. Non-linear correlation (Spearman's) 186 between absolute change and TTP was determined for both pH and [HCO₃-]. Absolute change 187 in pH and [HCO₃] and TTP pH and [HCO₃] were also assessed using Spearman's correlation. 188 Calculations were completed using Microsoft® Excel 2019 (Microsoft Inc, Redmond, WA, 189 USA) and statistical procedures were completed using SPSS version 29 (IBM, Chicago, IL, 190 USA).

191

192 **Results**

193 Differences Between Ingestion Volumes

194 A significant effect of condition was observed for blood [HCO₃⁻] (F (1.8,24.0) = 5.836, p =

195 0.002, (η_G^2) , = 0.0982), pH (F (3, 39) = 3.195, p = 0.034, (η_G^2) , = 0.0509) and [Na⁺] (F (3,39) =

196 13.444, p < 0.001, (η_c^2) , = 0.2716) (Figure 1). Mean blood [HCO₃⁻] was ~1 mmol·L⁻¹ greater 197 following 0.5 versus 0.4 g kg⁻¹ BM SC, which was significant in SC5b (29.26 ± 0.30) but not 198 SC5a (29.36 ± 0.42). Small elevations in blood pH from baseline were also apparent following 199 0.5 g kg⁻¹ BM, although further analysis was unable to detect any specific differences between 200 each condition. Lastly, small significant increases ($\leq 2 \text{ mmol}_{\times}L^{-1}$) in blood [Na⁺], were noted 201 for SC5a (145 \pm 0.5 mmol·L⁻¹) and SC5b (146 \pm 0.6 mmol·L⁻¹) compared to SC4a (142 \pm 0.5 202 mmol·L⁻¹, both p < 0.05) but not SC4b (144 ± 0.5 mmol·L⁻¹). 203 204 Figure 1 About Here 205 206 A significant effect of time, with no combined interaction effects, was demonstrated for blood $[HCO_{3}]$ (F (2.0, 25.8) = 212.3, p < 0.001, (η_{G}^{2}) , = 0.6544), pH (F (14, 182) = 71.638, p < 0.001, 207 (η_G^2) , = 0.4342) and [Na⁺] (F (14, 182) = 40.116, *p* < 0.001, (η_G^2) , = 0.2016). Comparing blood 208 209 [HCO₃-] at individual timepoints, a notable increase relative to the control was observed in all conditions from 68 min post-ingestion (F (4, 52) = 23.862, p < 0.001, (η_G^2), = 0.7525), and 210 remained 238 min post-ingestion (F (4,52) = 87.449, p < 0.001, (η_G^2) , = 0.7234). Differences 211 212 relative to control arose earlier for blood pH, starting from 51 min (F (2.6, 33.3) = 18.909, p < 213 0.001, (η_G^2) , = 0.3962) and again remaining 238 min post-ingestion (F (4, 52) = 46.890, p < 214 0.001, (η_G^2) , = 0.6543) in all conditions. While differences were highlighted at 102 and 153+ 215 min, blood [Na⁺] was similar between conditions throughout the sampling window. Further 216 analysis revealed no difference between conditions for absolute change in blood [HCO3-] or 217 pH (both p > 0.05). For TTP pH, a difference of ~40 min emerged between SC5b and SC4b 218 $(182 \pm 51 \text{ vs.} 143 \pm 47 \text{ min}, p = 0.048)$, with no further differences between conditions, nor for 219 $TTP[HCO_3^-].$ 220

A moderate correlation between TTP and absolute change in $[HCO_3^-]$ was observed postingestion of 0.5 g·kg⁻¹ BM SC (r_s (26) = 0.398, p = 0.036) but not 0.4 g·kg⁻¹ BM SC (r_s (26) = 223 0.245, p = 0.209). Neither 0.5 or 0.4 g·kg⁻¹ BM demonstrated an acceptable correlation 224 between TTP and absolute change in blood pH (r_s (26) = - 0.033, p = 0.866 and r_s (26) = 0.201, 225 p = 0.305, respectively). There was no correlation between TTP blood [HCO₃⁻] and TTP blood 226 pH following 0.5 (r_s (26) = 0.286, p = 0.141) or 0.4 g·kg⁻¹ BM (r_s (26) = 0.235, p = 0.228). For 227 absolute change in both measures, a moderate correlation was apparent following 0.5 g·kg⁻¹ 228 BM SC (r_s (26) = 0.416, p = 0.028), but not 0.4 g·kg⁻¹ (r_s (26) = 0.329, p = 0.087).

229

230

239 240

241

231 Reliability of blood HCO₃⁻, pH and Na⁺

Blood [HCO₃⁻] displayed good reliability post-ingestion of both 0.5 (r = 0.840, p < 0.001) and 0.4 g·kg⁻¹ BM SC (r = 0.771, p = 0.006), with moderate sTE (0.63 and 0.78, respectively) (Figure 2a). Blood pH also displayed good reliability following 0.5 g·kg⁻¹ BM SC (r = 0.819, p = 0.002, sTE = 0.67), but only moderate reliability following 0.4 g·kg⁻¹ BM SC, although this was non-significant (r = 0.520, p = 0.099, sTE = 1.36) (Figure 2b). Blood [Na⁺] displayed moderate reliability for both 0.5 (r = 0.728, p = 0.013, sTE = 0.86) and 0.4 g·kg⁻¹ BM SC (r = 0.667, p = 0.029, sTE = 1.00) (Figure 2c).

Figure 2 About Here

242 243 Reliability of TTP was greater for pH, with moderate reliability following both 0.5 (r = 0.676, p 244 = 0.026, sTE = 1.05) and 0.4 g kg⁻¹ BM SC (r = 0.679, pp = 0.025, sTE = 0.91). Comparatively, 245 blood [HCO₃⁻] displayed poor reliability for both 0.5 (r = 0.183, p = 0.361, sTE = 5.38) and 0.4 246 $g kg^{-1}$ BM SC (r = 0.290, p = 0.273, sTE = 2.50). Absolute change in blood [HCO₃-] and pH 247 both demonstrated good reliability following 0.5 g kg⁻¹ BM SC (r = 0.844, p = < 0.001, sTE = 248 0.81 and r = 0.811, p = 0.003, sTE = 0.01, respectively). Post-ingestion of 0.4 g kg⁻¹ BM SC, 249 absolute change was moderately reliable for both [HCO₃-] (r = 0.505, p = 0.109, sTE = 1.29) and pH (r = 0.536, p = 0.090, sTE = 0.02). Both TTP and absolute change in [HCO₃] and pH 250 251 displayed large inter-individual variation (Table 1).

252

253	Table 1 About Here
254	
255	Gastrointestinal Symptoms
256	Total symptoms displayed excellent reliability following 0.5 g·kg ⁻¹ BM SC (r = 0.932, p < 0.001,
257	sTE = 0.38) and good reliability post-ingestion of 0.4 g·kg ⁻¹ BM (r = 0.863, p < 0.001, sTE =
258	0.56). Across all conditions, all participants reported a pooled total GIS of 566 AU. In total, 8
259	of 14 participants reported no GIS across SC5 and SC4 (see Table 2 for individual symptoms).
260	One participant (14) reported a total GIS of 357 AU across all conditions, equating to 63% of
261	all AU. Total symptom scores (ranks) were similar between conditions (H(3) = 0.929, p =
262	0.818) with the highest score in SC5a (30.43), compared to SC4a (29.39), SC5b (27.93) and
263	SC4b (26.25), respectively.
264	
265	
266	Table 2 About Here
267	
268	Overall, TTP GIS was not significantly different between conditions (H(3) = 0.929, p = 0.818).
269	Reliability of TTP GIS following 0.5 g kg ⁻¹ BM SC was excellent (r = 0.918, p < 0.001, sTE =
270	0.42) demonstrating a range of 85 (102-17) and 34 (51-17) min for SC5b and SC5a,
271	respectively. The largest range in TTP GIS occurred in SC4a (204 min (221-17)) compared to
272	SC4b (34 min (64-34)), corresponding to good reliability for 0.4 g·kg ⁻¹ BM ($r = 0.791$, $p = 0.004$,
273	sTE = 0.73).
274	
275	Discussion
276	This study determined the reliability of blood [HCO3-], pH and [Na+] following acute,
277	individualised doses of encapsulated SC, to inform the efficacy of an approach to SC ingestion
278	based on individual TTP alkalosis (blood [HCO ₃ -] and/or pH). Firstly, blood [HCO ₃ -] and pH
279	responses displayed good reliability post-ingestion of 0.5 g kg ⁻¹ BM SC. Post-ingestion of 0.4

g·kg⁻¹ BM SC, blood [HCO₃-] maintained good reliability, versus moderate reliability for pH. The

281 blood [Na⁺] response was moderately reliable post-ingestion of both 0.5 and 282 0.4 g·kg⁻¹ BM SC. Secondly, TTP alkalosis demonstrated limited reliability for both blood pH 283 and [HCO₃-]. Blood pH displayed moderate reliability between repeated ingestion of 0.5 and 284 0.4 g kg⁻¹ BM SC against poor reliability for [HCO₃-]. Collectively, data suggest that while the 285 magnitude of blood alkalosis, particularly [HCO3-], appears reliable between repeated 286 ingestion of potentially ergogenic doses of SC (Urwin et al., 2021b; Cerullo et al., 2020), a 287 strategy based on individual TTP alkalosis cannot be recommended. Indeed, blood [HCO₃-] 288 peaked earlier (102-221 min) post-ingestion of 0.5 g kg⁻¹ BM SC than previously reported (188-289 300 min) (Urwin et al., 2021a; 2021b; Cerullo et al., 2020), which was similar within-and-290 between doses. This may be partly explained by the provision of a carbohydrate meal (1.75 291 g kg⁻¹ BM) in some studies (Urwin et al., 2021a), opting to resemble real-world practice rather 292 than isolate supplementation effects through a 4 h fast. Whilst 10% of food may remain in the 293 stomach after this period (Joneset al. 2016), meaning residual effects may remain even when 294 fasted, it is possible that meal volume, composition and texture may have contributed to the 295 differing timeframes (Gough et al. 2017a). Herein, it is also possible that capsule volume and 296 size may have contributed to variability in TTP. Indeed, Middlebrook et al. (2021) 297 demonstrated that TTP [HCO₃⁻] was significantly faster in smaller (size '0' = 94 \pm 24 min) 298 compared to medium (size '00' = 141 \pm 27 min) and larger capsules (size '000' = 121 \pm 29 299 min) demonstrating a non-linear relationship between capsule size and TTP.

300

301 Previous discussion has criticised individualised TTP as a strategy to optimise extracellular 302 buffer ingestion (de Oliveira et al., 2020). This approach requires access to a blood gas 303 analyser, for lengthy time-course measurement of blood [HCO3-] responses. de Oliveira et al., 304 (2020) also suggest that TTP assumes that increases in circulating [HCO₃-] are substantially 305 greater at peak, versus standardised timepoints. When provided aqueously, mean increases 306 in [HCO₃⁻] shown at TTP by Gough et al. (2017b) ($6.5 \pm 1.3 \text{ mmol L}^{-1}$) were similar to increases 307 shown following 60 min; 6.1, 5.1 and 5.7 mmol L^{-1} (Gough et al., 2017a; Jones et al., 2016; 308 Dias et al., 2015), 90 min; 6.5 and 6.1 mmol^{-L-1} (Gough et al., 2017a; Jones et al., 2016) and 309 120 min; 6.5 and 5.6 mmol L⁻¹ (Gough et al., 2017a; Jones et al., 2016) post-ingestion of 0.3 310 g kg⁻¹ BM SB. Blood [HCO₃-] was also similar 60, 120 and 180 min post-ingestion of gelatine-311 encapsulated SB (Siegler et al., 2012), leading de Oliveira et al. (2020) to question the utility 312 of ingestion timing overall. Authors proposed a "window of ergogenicity", estimating that >80% 313 of individuals from the population may experience increased blood [HCO₃⁻] of +5 mmol·L⁻¹ 314 between 75-240 min post-ingestion and +6 mmol·L⁻¹ between 90-225 min. Subsequently, de 315 Oliveira et al. (2021) linked greater exercise performance effects to medium (4-6 mmol L⁻¹) 316 and large (> 6 mmol·L⁻¹) increases in blood [HCO₃-], relative to small (\leq 4 mmol·L⁻¹). While 317 blood acid-base kinetics may vary, a similar window of ergogenicity may exist for SC.

318

319 Blood [HCO₃] was elevated above control in all conditions from 68 min, remaining elevated at 320 238 min post-ingestion. Absolute change ranged between 1.8-8.3 mmol·L⁻¹ post-ingestion of 321 0.5 g kg⁻¹ BM SC and 4.6-8.6 mmol L⁻¹ following 0.4 g kg⁻¹ BM SC. Except four instances (all 322 SC5) where absolute change did not exceed 4 mmol L⁻¹ (1.5, 1.8, 2.9 and 3.8 mmol L⁻¹), SC increased by 4, 5 and 6+ mmol L^{-1} in 93%, 76% and 48% of all instances, respectively. 323 324 Excluding outliers, absolute change in blood [HCO3-] remained lower than the 325 6.8-8.9 mmol⁻¹ previously reported (Urwin et al., 2022; 2021a; 2019), demonstrating variable 326 HCO₃⁻ kinetics, albeit within a potentially ergogenic range. Moreover, absolute change in blood 327 [HCO₃⁻] displayed good reliability (r = 0.844) post-ingestion of 0.5 g kg⁻¹ BM SC, versus 328 moderate reliability following 0.4 g kg⁻¹ BM SC (r = 0.505). An ingestion strategy based on 329 absolute, rather than TTP responses post-ingestion of 0.5 g kg⁻¹ BM SC, may present the most 330 effective strategy to achieve an ergogenic effect.

331

Alongside inducing sufficient blood alkalosis, reducing the incidence/severity of GIS remains a key component of effective SC ingestion strategies. Previously, SC has been associated with reduced incidence of GIS versus SB (Requena et al., 2005) although recently, GIS has been found to be minor for both substances, emerging 80-90 min post-ingestion for encapsulated SC, compared to 35-50 min for SB (Urwin et al., 2022). In total, 8 of 14 (57%) 337 participants reported zero GIS. However, one participant experienced marked symptoms, 338 representing 63% of the total pooled AU (357/566), suggesting that while GIS may be minor 339 for most, some participants may still respond negatively to SC. Despite associations between 340 greater ingested dose and GIS incidence/severity (Urwin et al., 2019; McNaughton, 1990), GIS was similar between conditions. Furthermore, both TTP peak and total symptoms 341 342 provided excellent-to-good reliability for 0.5 and 0.4 g kg⁻¹ BM SC, respectively. This may be explained by 7/9 instances (78%) of peak symptoms following 0.5 g kg⁻¹ BM SC emerging at 343 344 the first timepoint post-ingestion (17 min). Participants linked this finding to the large volume 345 of capsules ingested, contributing to a less palatable experience. Palatability may be 346 characterized as the overall sensory experiences and level of preference for a food/fluid. Urwin 347 et al. (2019) observed an improved palatability for encapsulated over aqueous SC, with similar 348 GIS. This preference may relate to the excessively salty taste in the latter, an effect potentially 349 lost here due to the larger volumes of capsules (55 \pm 6 vs. 36 \pm 6) ingested – without a 350 carbohydrate-rich meal. Individuals may seek to utilize split-dosing (Heibel et al., 2018) or 351 more novel carbohydrate hydrogel delivery systems (Gough & Sparks, 2024) to limit the total 352 capsules consumed, without impacting GIS.

353

354

355 **Conclusion**

356 The magnitude of (and displacement in) blood alkalosis following acute, individualized doses 357 of SC, particularly [HCO₃-], displays good reliability. Conversely, TTP blood alkalosis was not 358 reliable. This may be explained by the impact of capsule volume/size on blood acid-base 359 kinetics, which may also explainto reported GIS.. Alternatively to TTP approaches, strategies 360 supported by the sustained/absolute increases in [HCO₃-] observed between 68-238 min post-361 ingestion, may commence exercise within a generalised timeframe post-ingestion of 0.5 g kg⁻ 362 ¹ BM SC (>68 min) for a more precise, reliable response than previously reported. The 363 reliability of subsequent exercise performance thereafter should be addressed, alongside 364 alternate, practical approaches to SC ingestion than large quantities of capsules.

380 References

Boegman, S., Stellingwerff, T., Shaw, G., Clarke, N., Graham, K., Cross, R. & Siegler,
J.C. (2020). The impact of individualizing sodium bicarbonate supplementation strategies on
world-class rowing performance. *Frontiers in Nutrition*, p.138.
<u>https://doi.org/10.3389/fnut.2020.00138</u>.

Boekema, P.J., Samsom, M., van Berge Henegouwen, P. & Smout, P. (1999). Coffee and gastrointestinal function: facts and fiction: a review. *Scandinavian Journal of Gastroenterology*, *34*(230), pp.35-39. <u>https://doi.org/10.1080/003655299750025525</u>

Bishop, D., Edge, J., Davis, C. & Goodman, C. (2004). Induced metabolic alkalosis affects muscle metabolism and repeated-sprint ability. *Medicine and Science in Sports and Exercise*, 36(5), pp.807-813. <u>https://doi.org/10.1249/01.mss.0000126392.20025.17</u> Carr, A.J., Hopkins, W.G. and Gore, C.J. (2011). Effects of acute alkalosis and acidosis
 on performance: a meta-analysis. *Sports medicine*, *41*, pp.801-814.
 https://doi.org/10.2165/11591440-00000000-00000

394 Cerullo, G., Parimbelli, M., Perna, S., Pecoraro, M., Liguori, G., Negro, M. & D'antona, 395 G. (2020). Sodium citrate supplementation: An updated revision and practical 396 recommendations on exercise performance, hydration status, and potential 397 risks. *Translational Sports Medicine*, *3*(6), pp.518-525. https://doi.org/10.1002/tsm2.174

Cohen, J. (1988). Statistical Power Analysis for the Behavioural Sciences: Second
 Edition. Routledge. https://doi.org/10.4324/9780203771587

400Froio de Araujo Dias, G., da Eira Silva, V., de Salles Painelli, V., Sale, C., Giannini401Artioli, G., Gualano, B. & Saunders, B. (2015). (In) consistencies in responses to sodium402bicarbonate supplementation: a randomised, repeated measures, counterbalanced and403double-blindstudy. *PloSOne, 10*(11),p.e0143086.

404 <u>https://doi.org/10.1371/journal.pone.0143086</u>

Fitts R.H. (1994). Cellular mechanisms of muscle fatigue. Physiological Reviews.
74(1), pp.49–94. https://doi.org/10.1152/physrev.1994.74.1.49

Gough, L.A., Deb, S.K., Sparks, A.S. & McNaughton, L.R. (2017a). The reproducibility of blood acid base responses in male collegiate athletes following individualised doses of sodium bicarbonate: a randomised controlled crossover study. *Sports Medicine*, *47*, pp.2117-

410 2127. <u>https://doi.org/10.1007/s40279-017-0699-x</u>

Gough, L.A., Deb, S.K., Sparks, A. & McNaughton, L.R. (2017b). The reproducibility of 4-km time trial (TT) performance following individualised sodium bicarbonate supplementation: a randomised controlled trial in trained cyclists. *Sports Medicine-Open*, *3*, pp.1-10. <u>https://doi.org/10.1186/s40798-017-0101-4</u>

Gough, L.A. & Sparks, S.A. (2024). The Effects of a Carbohydrate Hydrogel System
for the Delivery of Bicarbonate Mini-Tablets on Acid–Base Buffering and Gastrointestinal
Symptoms in Resting Well-trained Male Cyclists. *Sports Medicine-Open* 10, 17.
https://doi.org/10.1186/s40798-024-00684-x

- Hausswirth, C., Bigard A.X., Lepers, R., Berthelot, M. & Guezennec, C.Y.
 (1995). Sodium citrate ingestion and muscle performance in acute hypobaric
 hypoxia. *European Journal of Applied Physiology and Occupational Physiology*. 19; 71, pp.
 362-368. https://doi.org/10.1007/BF00240418.
- Heibel, A.B., Perim, P.H., Oliveira, L.F., McNaughton, L.R. & Saunders, B. (2018).
 Time to optimize supplementation: modifying factors influencing the individual responses to
- 425 extracellular buffering agents. *Frontiers in Nutrition*, 5, pp.35.
 426 <u>https://doi.org/10.3389/fnut.2018.00035</u>
- Hopkins, W.G. (2000). Measures of reliability in sports medicine and science. *Sports Medicine*, *30*, pp.1-15. https://doi.org/10.2165/00007256-200030010-00001.
- 429 Johnston, J.D. (2014). Physiological links between circadian rhythms, metabolism and
- 430 nutrition. *Experimental Physiology*, 99(9), pp.1133-1137.
- 431 <u>https://doi.org/10.1113/expphysiol.2014.078295</u>
- 432 Jones, R.L., Stellingwerff, T., Artioli, G.G., Saunders, B., Cooper, S. & Sale, C., (2016).
- 433 Dose-response of sodium bicarbonate ingestion highlights individuality in time course of blood
- 434 analyte responses. International Journal of Sport Nutrition and Exercise metabolism, 26(5),
- 435 pp.445-453. <u>https://doi.org/10.1123/ijsnem.2015-0286</u>
- Keyser, R.E. (2010). Peripheral fatigue: high-energy phosphates and hydrogen
 ions. *PM&R*, 2(5), pp.347-358. <u>https://doi.org/10.1016/j.pmrj.2010.04.009</u>
- 438 Koo, T.K. & Li, M.Y. (2016). A guideline of selecting and reporting intraclass correlation
- 439 coefficients for reliability research. *Journal of Chiropractic Medicine*, *15*(2), pp.155-163.
- 440 Lassen, T.A., Lindstrøm, L., Lønbro, S. & Madsen, K. (2021). Increased Performance
- 441 in Elite Runners Following Individualized Timing of Sodium Bicarbonate
- 442 Supplementation. International Journal of Sport Nutrition and Exercise Metabolism, 31(6),
- 443 pp.453-459. <u>https://doi.org/10.1123/ijsnem.2020-0352</u>
- 444 McNaughton, L.R. (1990). Sodium citrate and anaerobic performance: implications of
- 445 dosage. European Journal of Applied Physiology and Occupational Physiology, 61, pp.392-
- 446 397. <u>https://doi.org/10.1007/BF00236058</u>

Miller, P., Robinson, A.L., Sparks, S.A., Bridge, C.A., Bentley, D.J. & McNaughton,
L.R. (2016). The effects of novel ingestion of sodium bicarbonate on repeated sprint
ability. *The Journal of Strength & Conditioning Research*, *30*(2), pp.561-568,
http://doi.org/10.1519/JSC.00000000001126

451Newbury, J.W., Cole, M., Kelly, A.L., Chessor, R.J., Sparks, S.A., McNaughton, L.R.452& Gough, L.A. (2021). The time to peak blood bicarbonate (HCO_3^-), pH, and the strong ion453difference (SID) following sodium bicarbonate ($NaHCO_3^-$) ingestion in highly trained454adolescentswimmers. *Plos*0ne, 16(7),p.e0248456.

455 <u>https://doi.org/10.1371/journal.pone.0248456</u>

de Oliveira, L.F., Dolan, E., Swinton, P.A., Durkalec-Michalski, K., Artioli, G.G.,
McNaughton, L.R. & Saunders, B. (2022). Extracellular buffering supplements to improve
exercise capacity and performance: A comprehensive systematic review and metaanalysis. *Sports Medicine*, pp.1-22. https://doi.org/10.1007/s40279-021-01575-x

de Oliveira, L.F., Saunders, B., Yamaguchi, G., Swinton, P. & Giannini Artioli, G.,
(2020). Is individualization of sodium bicarbonate ingestion based on time to peak
necessary?. *Medicine and Science in Sports and Exercise*, 52(8).
https://doi.org/10.1249/MSS.00000000002313

de Salles Painelli, V. & Junior, A.H.L. (2018). Thirty years of investigation on the ergogenic effects of sodium citrate: is it time for a fresh start?. *British Journal of Sports Medicine*, 52(14), pp.942-943. <u>http://doi.org/10.1136/bjsports-2016-096516</u>

Peacock, J., Sparks, S.A., Middlebrook, I., Hilton, N.P., Tinnion, D., Leach, N.,
Saunders, B. & McNaughton, L.R. (2021). Extracellular buffer choice influences acid-base
responses and gastrointestinal symptoms. *Research in Sports Medicine*, *29*(6), pp.505-516.

470 Poupin, N., Calvez, J., Lassale, C., Chesneau, C. & Tomé, D. (2012). Impact of the 471 diet on net endogenous acid production and acid–base balance. *Clinical Nutrition*, *31*(3),

472 pp.313-321. <u>https://doi.org/10.1016/j.clnu.2012.01.006</u>

473 Remer, T. (2001). Influence of nutrition on acid-base balance-metabolic
474 aspects. *European Journal of Nutrition*, 40, pp.214-220. <u>https://doi.org/10.1007/s394-001-</u>
475 <u>8348-1</u>

Requena, B., Zabala, M., and Padial, P. (2005). Sodium bicarbonate and sodium
citrate: ergogenic aids? *Journal of Strength and Conditioning Research*. 19(1), pp.213–222.
https://doi.org/10.1519/00124278-200502000-00036

Romijn, J.A., Coyle, E.F., Sidossis, L.S., Gastaldelli, A., Horowitz, J.F., Endert, E. and
Wolfe, R.R. (1993). Regulation of endogenous fat and carbohydrate metabolism in relation to
exercise intensity and duration. *American Journal of Physiology-Endocrinology And Metabolism*, 265(3), pp.380-391. <u>https://doi.org/10.1152/ajpendo.1993.265.3.E380</u>

Siegler, J.C., Marshall, P.W., Bray, J. and Towlson, C. (2012). Sodium bicarbonate
supplementation and ingestion timing: does it matter?. *The Journal of Strength & Conditioning Research*, 26(7), pp.1953-1958. <u>https://doi.org/10.1519/JSC.0b013e3182392960</u>

Sparks, A. S., Williams, E. L., Jones, H. J., Bridge, C. A., Marchant, D., & McNaughton,
L. (2016). Test-retest reliability of a 16.1 km time trial in trained cyclists using the
CompuTrainer ergometer. *Journal of Science and Cycling*, *5*(3), pp. 35-41.

Stables, R.G., Kasper, A.M., Sparks, S.A., Morton, J.P. & Close, G.L. (2021). An
assessment of the validity of the remote food photography method (Termed Snap-N-Send) in
experienced and inexperienced sport nutritionists. *International Journal of Sport Nutrition and Exercise Metabolism*, *31*(2), pp.125-134. <u>https://doi.org/10.1123/ijsnem.2020-0216</u>

493 Stadlbauer, V., Wallner, S., Stojakovic, T. & Smolle, K.H. (2011). Comparison of 3 494 different multianalyte point-of-care devices during clinical routine on a medical intensive care 495 unit. *Journal of Critical Care*, *26*(4), pp.433-e1. <u>https://doi.org/10.1016/j.jcrc.2010.09.003</u>

496 Urwin, C.S., Snow, R.J., Condo, D., Snipe, R., Wadley, G.D. & Carr, A.J. (2021b).
497 Factors Influencing Blood Alkalosis and Other Physiological Responses, Gastrointestinal
498 Symptoms, and Exercise Performance Following Sodium Citrate Supplementation: A

Review. International journal of Sport Nutrition and Exercise Metabolism, 31(2), pp.168-186.
https://doi.org/10.1123/ijsnem.2020-0192.

501 Urwin, C.S., Snow, R.J., Condo, D., Snipe, R.M., Wadley, G.D., Convit, L. & Carr, A.J.
502 (2022). A Comparison of Sodium Citrate and Sodium Bicarbonate Ingestion: Blood Alkalosis
503 and Gastrointestinal Symptoms. *International Journal of Sport Nutrition and Exercise*504 *Metabolism*, 33(1), pp.1-10. <u>https://doi.org/10.1123/ijsnem.2022-0083</u>.

505Urwin, C.S., Snow, R.J., Orellana, L., Condo, D., Wadley, G.D. & Carr, A.J. (2021a).506Does varying the ingestion period of sodium citrate influence blood alkalosis and507gastrointestinal508https://doi.org/10.1371/journal.pone.0251808.

509 Urwin, C.S., Snow, R.J., Orellana, L., Condo, D., Wadley, G.D. & Carr, A.J. (2019).

510 Sodium citrate ingestion protocol impacts induced alkalosis, gastrointestinal symptoms, and

511 palatability. *Physiological Reports*, 7(19), p.e14216. <u>https://doi.org/10.14814/phy2.14216</u>.

512 Van Loon, L.J., Greenhaff, P.L., Constantin-Teodosiu, D., Saris, W.H. & 513 Wagenmakers, A.J. (2001). The effects of increasing exercise intensity on muscle fuel 514 utilisation in humans. The Journal of Physiology, 536(1), pp.295-304. 515 https://doi.org/10.1111/j.1469-7793.2001.00295.x.

- 516 Westerterp-Plantenga, M., Diepvens, K., Joosen, A.M., Bérubé-Parent, S. & Tremblay,
 517 A., (2006). Metabolic effects of spices, teas, and caffeine. *Physiology & Behaviour*, 89(1),
- 518 pp.85-91. <u>https://doi.org/10.1016/j.physbeh.2006.01.02.</u>
- 519
- 520
- 521
- 522
- 523
- 524
- 525
- 52.
- 526

527

- 528
- 529
- 530
- 531 Figure titles
- 532 **Figure 1.** Mean blood analyte responses for bicarbonate (top), pH (middle) and sodium
- 533 (bottom) following the ingestion of 0.5 (left) and 0.4 (right) g·kg⁻¹ BM sodium citrate (SC)
- 534 (repeated 'A' and 'B') or 0.07 g·kg⁻¹ BM sodium chloride control (all). Some error bars are
- 535 omitted for clarity.
- 536
- Figure 2. Mean (±SD) area under the curve (AUC) for blood bicarbonate (HCO₃⁻) (A), pH (B)
 and sodium (Na⁺) (C) responses, following the ingestion of either 0.5 g·kg⁻¹ (SC5) or 0.4 g·kg⁻
 ¹ (SC4) body mass (BM) sodium citrate (SC). Where 'r' represents the intraclass correlation
 coefficient (ICC), '*' denotes a significant correlation between conditions and 'CV' illustrates
 the technical error, expressed as a coefficient of variation (%).



Figure 1. Mean blood analyte responses for bicarbonate (top), pH (middle) and sodium (bottom) following the ingestion of 0.5 (left) and 0.4 (right) g·kg⁻¹ BM sodium citrate (SC) (repeated 'A' and 'B') or 0.07 g·kg⁻¹ BM sodium chloride control (all). Some error bars are omitted for clarity.



Figure 2. Mean (± SD) area under the curve (AUC) for blood bicarbonate (HCO_3^{-1}) (A), pH (B) and sodium (Na⁺) (C) responses, following the ingestion of either 0.5 g·kg⁻¹ (SC5) or 0.4 g·kg⁻¹ (SC4) body mass (BM) sodium citrate (SC). Where 'r' represents the intraclass correlation coefficient (ICC), '*' denotes a significant correlation between conditions and 'CV' illustrates the technical error, expressed as a coefficient of variation (%).

 Table 1. Individual time to peak and peak absolute change from baseline in both blood pH and bicarbonate (HCO₃-) following 0.5 (SC5) and 0.4 (SC4) g·kg⁻¹ BM sodium citrate.

 23

	Time to peak (min)							Peak absolute change from baseline								
Participant	рН				HCO₃ (mmol·L ⁻¹)				рН				HCO ₃ (mmol·L ⁻¹)			
	SC5a	SC5b	SC4a	SC4b	SC5a	SC5b	SC4a	SC4b	SC5a	SC5b	SC4a	SC4b	SC5a	SC5b	SC4a	SC4b
1	170	170	204	187	170	102	153	136	0.08	0.7	0.08	0.06	7.5	5.9	5.0	4.9
2	136	153	204	119	170	170	187	136	0.11	0.09	0.09	0.08	7.6	7.3	7.5	6.1
3	170	238	153	136	102	204	85	153	0.07	0.10	0.03	0.05	6.0	7.2	5.7	4.5
4	102	85	187	102	136	136	153	170	0.05	0.07	0.07	0.09	3.8	4.9	5.1	5.7
5	119	119	136	136	221	204	136	136	0.11	0.13	0.11	0.09	6.6	5.4	4.9	4.9
6	136	136	204	136	170	136	204	170	0.08	0.07	0.09	0.07	6.2	6.2	7.2	5.8
7	119	204	119	85	119	204	102	153	0.03	0.06	0.07	0.08	1.8	2.9	5.4	5.8
8	68	136	85	102	119	170	102	187	0.10	0.14	0.07	0.13	1.5	5.4	4.6	5.0
9	238	238	153	170	187	187	238	170	0.06	0.10	0.08	0.10	5.9	7.0	6.1	7.1
10	85	238	187	187	136	136	187	187	0.09	0.10	0.10	0.14	7.0	8.2	5.0	7.4
11	153	187	136	136	187	187	153	119	0.07	0.08	0.08	0.07	8.3	8.3	6.3	7.0
12	136	187	187	187	102	136	170	187	0.03	0.05	0.09	0.08	4.8	4.6	6.7	5.5
13	153	238	204	136	153	204	85	136	0.07	0.08	0.08	0.06	6.8	7.2	6.6	5.6
14	221	221	204	187	153	119	119	170	0.09	0.07	0.09	0.09	5.9	6.1	8.6	6.7
Mean	143	182	169	143	152	164	148	158	0.07	0.09	0.08	0.09	5.7	6.2	6.1	5.9
Range	170	153	119	102	119	102	153	68	0.08	0.09	0.08	0.09	6.8	5.4	4.0	2.9
95% CI	96-190	131-233	130-208	108-178	117-187	128-200	102-194	136-181	0.05-0.09	0.06-0.12	0.06-0.10	0.07-0.11	3.6-7.8	4.7-7.7	4.9-7.3	5.0-6.8
SD	47	51	39	35	35	36	46	23	0.02	0.03	0.02	0.02	2.1	1.5	1.2	0.9
CV	32.8	27.7	22.9	24.5	23.0	21.8	31.3	14.3	33.9	29.8	23.1	29	36.1	24.1	19.3	15.4
SEM	12.6	13.5	10.3	9.4	9.3	9.5	12.4	6.0	0.01	0.01	0.01	0.01	0.5	0.4	0.3	0.2

CI = Confidence interval, SD = Standard Deviation, CV = Coefficient of Variation, SEM = Standard Error of Mean

Participant	SC	5a	SC5b)	SC	C4a	SC4b		
Faiticipant	Total symptoms (AU)	Peak symptom	Total symptoms (AU)	Peak symptom	Total symptoms (AU)	Peak symptom	Total symptoms (AU)	Peak symptom	
1	47	Stomach bloating	10	Nausea	14	Nausea/stomach ache	32	Nausea	
2	8	Nausea/stomach ache	None	None	40	Nausea	2	Nausea/stomach ache	
3	None	None	None	None	None	None	None	None	
4	None	None	None	None	None	None	None	None	
5	None	None	None	None	None	None	None	None	
6	None	None	None	None	None	None	None	None	
7	8	Nausea	7	Nausea	None	None	None	None	
8	23	Vomiting	12	Diarrhoea	2	Flatulence	None	None	
9	None	None	None	None	4	Bowel urgency	None	None	
10	None	None	None	None	None	None	None	None	
11	None	None	None	None	None	None	None	None	
12	None	None	None	None	None	None	None	None	
13	None	None	None	None	None	None	None	None	
14	49	Stomach bloating	54	Nausea	16	Bowel urgency	238	Bowel urgency	

Table 2. Individual gastrointestinal symptoms experienced following ingestion of sodium citrate 0.5 (SC5) and 0.4 (SC4) g·kg⁻¹ BM sodium citrate (SC).

Where more than one symptom of equally high severity occurred at the same time point, both symptoms are noted.

Where more than one symptom of equally high severity occurred at different time points, only the symptom which occurred earliest is noted.

DT, LM and AS contributed to the study conception and design. DT, BD and NH aided with data collection. DT, BD and AS worked on the analysis and interpretation of results. DT, BD, NH, LM and AS were all involved in manuscript preparation

Authors confirm that there are no funding or potential conflicts of interest to be declared.